Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety Study of Vildagliptin in Type 2 Diabetes
NCT00325429Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vildagliptin in type 2 diabetes mellitus (T2DM), sponsored by Novartis. Primary endpoint: Adverse events profile at 52 weeks. Started Apr 2006; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00325429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00325429.